Press Releases

Apr 01, 2020

Veracyte Announces Novel Gene Fusion Detection with the Afirma Xpression Atlas, Which May Inform Targeted Treatment Decisions for Thyroid Cancer Patients

Read More

Mar 02, 2020

Veracyte Announces Publication of Nearly 700-Patient Study Using Prosigna Breast Cancer Test to Identify Patients Likely to Benefit from Aggressive Chemotherapy

Read More

Feb 25, 2020

Veracyte Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides 2020 Financial Outlook

Read More

Feb 13, 2020

Veracyte to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Read More

Feb 06, 2020

Veracyte to Release Fourth Quarter and Full-Year 2019 Financial Results on February 25, 2020

Read More

Jan 08, 2020

Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma

Read More

Dec 03, 2019

Veracyte Acquires Exclusive License to NanoString Diagnostics Platform, Positioning Veracyte To Expand Its Genomic Testing Business Globally

Read More

Nov 02, 2019

Veracyte Announces New Data That Advance Understanding of Genomic Alterations Targeted by Precision Medicine Therapies for Thyroid Cancer

Read More

Oct 30, 2019

Veracyte Announces New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at 89th Annual Meeting of the American Thyroid Association

Read More

Oct 22, 2019

Veracyte Announces Third Quarter 2019 Financial Results and Business Progress

Read More